Bank of Montreal’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.5K | Buy |
11,896
+691
| +6% | +$950 | ﹤0.01% | 3503 |
|
|
2025
Q4 | $18K | Sell |
11,205
-1,825
| -14% | -$3.82K | ﹤0.01% | 3364 |
|
|
2025
Q3 | $35.6K | Buy |
13,030
+400
| +3% | +$1.33K | ﹤0.01% | 3191 |
|
|
2025
Q2 | $46K | Buy |
12,630
+46
| +0.4% | +$126 | ﹤0.01% | 3157 |
|
|
2025
Q1 | $24.2K | Buy |
+12,584
| New | +$25.7K | ﹤0.01% | 3186 |
|
|
2024
Q2 | – | Sell |
-68,475
| Closed | -$126K | – | 3827 |
|
|
2024
Q1 | $126K | Buy |
+68,475
| New | +$109K | ﹤0.01% | 3225 |
|
|
2021
Q2 | – | Sell |
-3,878
| Closed | -$12K | – | 3660 |
|
|
2021
Q1 | $12K | Sell |
3,878
-18,155
| -82% | -$65.4K | ﹤0.01% | 4261 |
|
|
2020
Q4 | $67K | Buy |
22,033
+14,354
| +187% | +$41.9K | ﹤0.01% | 3793 |
|
|
2020
Q3 | $21K | Sell |
7,679
-204,744
| -96% | -$1.8M | ﹤0.01% | 3810 |
|
|
2020
Q2 | $2.65M | Buy |
212,423
+212,254
| +125,594% | +$2.2M | ﹤0.01% | 1489 |
|
|
2020
Q1 | $1K | Sell |
169
-15,153
| -99% | -$118K | ﹤0.01% | 3932 |
|
|
2019
Q4 | $96K | Buy |
15,322
+2,202
| +17% | +$10.5K | ﹤0.01% | 3511 |
|
|
2019
Q3 | $52K | Buy |
13,120
+1,264
| +11% | +$5.42K | ﹤0.01% | 3601 |
|
|
2019
Q2 | $57K | Buy |
11,856
+11,105
| +1,479% | +$63.2K | ﹤0.01% | 3626 |
|
|
2019
Q1 | $6K | Sell |
751
-1,208
| -62% | -$8.29K | ﹤0.01% | 3986 |
|
|
2018
Q4 | $11K | Buy |
1,959
+888
| +83% | +$6.95K | ﹤0.01% | 3850 |
|
|
2018
Q3 | $9K | Buy |
1,071
+336
| +46% | +$3K | ﹤0.01% | 3941 |
|
|
2018
Q2 | $8K | Sell |
735
-57,543
| -99% | -$576K | ﹤0.01% | 4004 |
|
|
2018
Q1 | $555K | Sell |
58,278
-9,361
| -14% | -$131K | ﹤0.01% | 2174 |
|
|
2017
Q4 | $1.01M | Buy |
67,639
+12,755
| +23% | +$212K | ﹤0.01% | 1948 |
|
|
2017
Q3 | $1.08M | Buy |
54,884
+54,661
| +24,512% | +$840K | ﹤0.01% | 1935 |
|
|
2017
Q2 | $3K | Hold |
223
| – | – | ﹤0.01% | 3938 |
|
|
2017
Q1 | $2K | Hold |
223
| – | – | ﹤0.01% | 3815 |
|
|
2016
Q4 | $2K | Hold |
223
| – | – | ﹤0.01% | 3872 |
|
|
2016
Q3 | $2K | Hold |
223
| – | – | ﹤0.01% | 3840 |
|
|
2016
Q2 | $2K | Sell |
223
-50
| -18% | -$436 | ﹤0.01% | 3880 |
|
|
2016
Q1 | $2K | Sell |
273
-13,959
| -98% | -$113K | ﹤0.01% | 3960 |
|
|
2015
Q4 | $184K | Buy |
14,232
+14,182
| +28,364% | +$145K | ﹤0.01% | 2472 |
|
|
2015
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 3967 |
|
|
2015
Q2 | $1K | Hold |
50
| – | – | ﹤0.01% | 3815 |
|
|
2015
Q1 | $1K | Hold |
50
| – | – | ﹤0.01% | 3842 |
|
|
2014
Q4 | $1K | Buy |
+50
| New | +$717 | ﹤0.01% | 3889 |
|
Other funds holding AKBA
VCM
VPM
Bank of Montreal's AKBA Position: Q1 2026 in Review
Bank of Montreal increased its Akebia Therapeutics (AKBA) stake by 6.2% in Q1 2026, buying an estimated $950 and bringing the position to 11,896 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.
Bank of Montreal first reported a position in AKBA in Q4 2014 and has held it in 32 quarters since. The position peaked at $2.65M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Bank of Montreal held 11,896 shares of Akebia Therapeutics worth $16.5K as of Q1 2026.
- Bank of Montreal bought 691 Akebia Therapeutics shares in Q1 2026, an estimated $950.
- Akebia Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #3503 holding.
- Bank of Montreal first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 32 quarters since.
- Bank of Montreal's Akebia Therapeutics position peaked at $2.65M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.